Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Cash & Current Investments: 2019-2024

Historic Cash & Current Investments for Caribou Biosciences (CRBU) over the last 6 years, with Dec 2024 value amounting to $209.5 million.

  • Caribou Biosciences' Cash & Current Investments fell 35.46% to $147.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $749.2 million, marking a year-over-year decrease of 32.66%. This contributed to the annual value of $209.5 million for FY2024, which is 36.28% down from last year.
  • As of FY2024, Caribou Biosciences' Cash & Current Investments stood at $209.5 million, which was down 36.28% from $328.8 million recorded in FY2023.
  • In the past 5 years, Caribou Biosciences' Cash & Current Investments ranged from a high of $375.8 million in FY2021 and a low of $16.0 million during FY2020.
  • For the 3-year period, Caribou Biosciences' Cash & Current Investments averaged around $262.0 million, with its median value being $247.7 million (2022).
  • Per our database at Business Quant, Caribou Biosciences' Cash & Current Investments slumped by 61.16% in 2020 and then surged by 2,255.87% in 2021.
  • Over the past 5 years, Caribou Biosciences' Cash & Current Investments (Yearly) stood at $16.0 million in 2020, then spiked by 2,255.87% to $375.8 million in 2021, then crashed by 34.10% to $247.7 million in 2022, then skyrocketed by 32.77% to $328.8 million in 2023, then slumped by 36.28% to $209.5 million in 2024.